U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMR co.	ntroi number.					
	Substitute for fo	rm 14	49/PTO		Complete if Known	70. un
	INFORMATION	DISC	LOSURE	Application Number	10/677,857	1 8
	STATEMENT B	Y AP	PLICANT	Filing Date	10/3/2003	NOV 0 3 2010 \$
	Data Cubasittadi N		har 2 2040	First Named Inventor	Cooper et al.	12 M
	Date Submitted: N	ovem	ber 3, 2010	Art Unit	1651	[a] [a]
	(use as many shee	ets as	necessary)	Examiner Name	Thane E. Underd	ahl & MADEMARKO
Sheet	1	of	3	Attorney Docket Number	029318-0981	TADEMIA

	U.S. PATENT DOCUMENTS							
Examin Ci	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant			
er Initials*	er No 1	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear			
	A1	2002/002294 A1	1/3/2002	Cushman				
	A2	2002/0055462	05/2002	Reed et al.				
	A3	2002/0165265	11/2002	Hunter et al.				
	A4	5,466,440	11/1995	Ruddy et al.				
	A5	5,510,118	4/23/1996	Swanson et al.				
	A6	5,521,168	05/1996	Clark				
	A7	6,068,858	5/30/2000	Liversidge et al.				
	A8	6,316,029	11/2001	Jain et al.				
	A9	6,395,300 B1	5/28/2002	Straub et al.				
	A10	2004/0033267 A1	2/19/2004	Merisko-Liversidge et al.				

			FOREIGN PATENT	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆						
	B1	WO 98/04291	02/05/1998	MUKHOPADHYAY et al.								
!		(English Equivalent to JP 2000-517299)										
<u> </u>	B2	WO 01/92584 A1	12/6/2001	Hubbel et al.								
<i></i>	B3	EP 0 602 702 A1	6/22/1994	June, Siegfield K.								
	B4	WO 00/32189	06/08/2000	Gao et al.								
	B5	WO 01/91750 A1	12/06/2001	Karim et al.								
	B6	WO 99/02665	01/21/1999	Liversidge et al.								
l	B7	EP 1 800 666 A1	06/27/2007	Merisko-Liversidge et al.		<u> </u>						
	B8	WO 03/080027 A1	10/02/2003	Merisko-Liversidge et al.								
	B9	WO 02/24163	3/28/2002	Ruddy et al.		↓						
<i>[</i>	B10	WO 90/15593	12/27/1990	Ytkemiska		┷						
	B11		10/20/1992	Liversidge et al.	ABSTRACT only *Corresp. U.S. Appln. 5,145,684, (prev. cited)							
1	B12	JP 8-507075	07/30/1996	Grinstaff et al.	ABSTRACT only							
	B13		09/01/1994	Grinstaff et al.	Corresp. Appln. to JP 8-507075							
	B14	JP 2004-513886	05/13/2004	Ruddy et al.	ABSTRACT Only Corresp. to WO 02/24163 (currently							

 $^{f H}$ All References Considered Unless Lined Through $\,$ /TU/ $\,$

	,	1111	`	•
Examiner Signature	Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

	Substitute for fo	rm 14	49/PTO	Complete if Known		
	INFORMATION	DISC	LOSURE	Application Number	10/677,857	
	STATEMENT B			Filing Date	10/3/2003	
			0 . 0040	First Named Inventor	Cooper et al.	
	Date Submitted: N	ovem	ber 3, 2010	Art Unit	1651	
	(use as many shee	ets as	necessary)	Examiner Name	Thane E. Underdahl	
Sheet	2	of	3	Attorney Docket Number	029318-0981	

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B15	WO 01/26635	4/19/2001	Bosch et al.		
	B16	JP 57-26615	2/12/1982	Kikazawa et al.	Eng. Abstract	
	B17	WO 98/14174 (JP 2001-501931)	04/09/1998	Desai et al.		
	B18	JP 2-167222	06/27/1990	Jiyoshiaanu et al.	Eng. Abstract and Eng. Translation	
	B19	EP 0 577 215	3/22/2000	Liversidge et al.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т ⁶
	C1	Damascelli et al., Intraarterial Chemotherapy with Polyoxyethylated Castor Oil Free Paclitaxel, Incorporated in Albumin Nanoparticles (ABI-007) Phase I Study of Patients with Squamous Cell Carcinoma of the Head and Neck and Anal Canal: Preliminary Evidence of Clinical Activity; 2001 Cancer, Vol. 92, No. 10, pp. 2592-2602.	
	C2	Office Action cited in related U.S. Patent Application No. 11/928,278, dated 12/28/2009.	
	СЗ	Office Action cited in related U.S. Patent Application No. 11/928,250, dated 12/29/2009.	
	C4	Office Action cited in related U.S. Patent Application No. 11/928,289, dated 12/30/2009.	
	C5	Notice of Reasons for Rejections cited in related Japanese Patent Application No. 2003-577857, dated 03/29/2010.	
	C6	Office Action cited in related U.S. Patent Application No. 11/928,250, dated 8/4/2010.	
	C7	Office Action cited in related U.S. Patent Application No. 11/928,278, dated 8/4/2010.	
	C8	Office Action cited in related U.S. Patent Application No. 11/928,289, dated 8/3/2010.	
	C9	Office Action cited in related U.S. Patent Application No. 10/667,470, dated 7/27/2010.	

All References Considered Unless Lined Through /TU/

	•	· · · · · · · · · · · · · · · · · · ·
Examiner Signature	Date Considered	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

	Substitute for fo	rm 14	49/PTO	Complete if Known		
	INFORMATION	DISC	LOSURE	Application Number	10/677,857	
STATEMENT BY APPLICANT				Filing Date	10/3/2003	
	Date Submitted: November 3, 2010 (use as many sheets as necessary)			First Named Inventor	Cooper et al.	
				Art Unit	1651	
				Examiner Name	Thane E. Underdahl	
Sheet	3	of	3	Attorney Docket Number	029318-0981	

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
C10	Office Action cited in related U.S. Patent Application No. 09/337,675, dated 8/30/2010.	
C11	Josefsson et al., "Suppression of Type II Collagen-Induced Arthritis by the Endogenous Estrogen Metabolite 2-Methoxyestradiol," <i>Arthritis & Rheumatism</i> , Vol. 40, Issue 1, pp. 154-163 (1997).	
C12	Office Action cited in related U.S. Patent Application No. 12/870,722, dated 10/7/2010.	
C13	Office Action cited in related U.S. Patent Application No. 12/870,745, dated 10/7/2010.	
C14	Office Action cited in related U.S. Patent Application No. 12/076,247, dated 8/5/2010.	
C15	Office Action cited in related U.S. Patent Application No. 12/320,431, dated 9/30/2010.	
C16	Merriam-Webster's Collegiate Dictionary, 10 th edition, Merriam-Webster Incorp.: Springfield, MA, 1993, pp. 311.	
C17	Office Action cited in related U.S. Patent Application No 10/667,470, dated July 27, 2010.	
C18	International Search Report for related International Patent Application No. PCT/US2009/036965, completed 06/19/2009.	
C19	Written Opinion of the International Searching Authority for related International Patent Application No. PCT/US2009/036965, completed 06/19/2009.	
C20	Notice of Rejections for related Japanese Patent Application No. 2003-577857 completed July 6, 2009, 3 pgs.	
C21	Notice of Decision to Grant dated 8/30/2010 cited in related Japanese Patent Application No. 2003-565446.	
C22	Canadian Office Action dated 3/10/2010, cited in related Canadian Patent Application No. 2,479,665.	
	No.¹ C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 C21	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Office Action cited in related U.S. Patent Application No. 09/337,675, dated 8/30/2010. 1 Josefsson et al., "Suppression of Type II Collagen-Induced Arthritis by the Endogenous Estrogen Metabolite 2-Methoxyestradiol," Arthritis & Rheumatism, Vol. 40, Issue 1, pp. 154-163 (1997). Office Action cited in related U.S. Patent Application No. 12/870,722, dated 10/7/2010. Office Action cited in related U.S. Patent Application No. 12/870,745, dated 10/7/2010. Office Action cited in related U.S. Patent Application No. 12/076,247, dated 8/5/2010. Office Action cited in related U.S. Patent Application No. 12/320,431, dated 9/30/2010. Merriam-Webster's Collegiate Dictionary, 10 th edition, Merriam-Webster Incorp.: Springfield, MA, 1993, pp. 311. Office Action cited in related U.S. Patent Application No 10/667,470, dated July 27, 2010. International Search Report for related International Patent Application No. PCT/US2009/036965, completed 06/19/2009. Written Opinion of the International Searching Authority for related International Patent Application No. PCT/US2009/036965, completed 06/19/2009. Notice of Rejections for related Japanese Patent Application No. 2003-577857 completed July 6, 2009, 3 pgs.

All References Considered Unless Lined Through

Examiner Signature	/Thane Underdahl/	Date Considered	6/4/11

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.